UNICREDIT BANK/CALL/ELI LILLY & CO/650/0.1/15.01.25 | Real-time BOERSE MUENCHEN 15:41:06 2024-06-25 EDT | ||
| 25.71 EUR | +2.92% |
|
| Current month | +38.82% | ||
| 1 month | +41.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 25.71 | +2.92% |
| 24-06-24 | 24.98 | +2.17% |
| 24-06-21 | 24.45 | +1.28% |
| 24-06-20 | 24.14 | -2.90% |
| 24-06-19 | 24.86 | +0.81% |
Real-time BOERSE MUENCHEN
Last update June 25, 2024 at 03:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HC6HFR |
| ISIN | DE000HC6HFR3 |
| Date issued | 2023-05-05 |
| Strike | 650 $ |
| Maturity | 2025-01-15 (204 Days) |
| Parity | 10 : 1 |
| Emission price | 1.65 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.14 € |
|---|---|
| Lowest since issue | 1.07 € |
| Spread | 0.27 € |
| Spread % | 1.04% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6
USD
Average target price
860.5
USD
Spread / Average Target
-4.87%
- Stock Market
- Warrants
- Warrant
